AGOMELATINE ETHOSOMES FOR ENHANCED TRANSDERMAL DRUG DELIVERY
DOI:
https://doi.org/10.22159/ijap.2024v16i6.52002Keywords:
Ethosomes, Agomelatine, Vesicle, Transdermal, Permeation, TEMAbstract
Objective: The current study aimed to prepare and optimize Agomelatine (AMN) ethosomes for enhanced transdermal drug delivery.
Methods: In this study cold method was employed to manufacture the AMN-loaded ethosomes with dissimilar quantities of Phosphatidyl Choline (PC): Cholesterol: Ethanol. Transmission Electron Microscopy (TEM) was employed to evaluate the appearance of the formed ethosomes. Other formulation parameters like vesicle size and zeta potential, polydispersity index, transition temperature, and entrapment efficiency were also investigated.
Results: The microscopy results showed that AMN ethosomes have a smooth surface. It was discovered that the AMN-3 formulation of transdermal ethosomes had 92.15±1.3 entrapment efficiency with good vesicle diameter. The release of agomelatine adhered to the zero-order release model. The polydispersity Index (PI) and zeta potential of the optimized formulation were found to be 0.209 and-14.09±1.95 mV, respectively. The maximum flux for the ethosome formulation (AMN-3) was 34.29 µg. h/cm2. A 10.71 fold increment was observed in the bioavailability of optimized formulation than control (oral suspension). A higher drug concentration in the blood suggested better systemic absorption of ethosomes. The optimized formula has a Tmax of 4.0±0.08h and 73.38±1.37 of Cmax. The AMN ethosomes were found to be more stable when stored at 4 °C.
Conclusion: The current study suggests that ethosomal vesicles may improve transdermal dispersion without causing skin irritation. Agomelatine-loaded ethosome has the potential to be one of the most important transdermal application techniques for the treatment of depression.
Downloads
References
Kaur P, Garg, V, Bawa P, Sharma R, Singh SK, Kumar B. Formulation, systematic optimization, in vitro, ex vivo, and stability assessment of transethosome based gel of curcumin. Asian J Pharm Clin Res. 2018;11(14). doi: 10.22159/ajpcr.2018.v11s2.28563.
Tomar P, Saji JM, Patel D, Thakkar H. Formulation and evaluation of solid-self micro emulsifying drug delivery system (S-SMEDDS) of agomelatine. Colloid J. 2023;85(2):276-86. doi: 10.1134/S1061933X22600014.
Barmpalexis P, Grypioti A, Vardaka E, Karagianni A, Kachrimanis K. Development of a novel amorphous agomelatine formulation with improved storage stability and enhanced bioavailability. J Pharm Sci. 2018;107(1):257-66. doi: 10.1016/j.xphs.2017.09.017, PMID 28989020.
Fatouh AM, Elshafeey AH, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. Drug Des Dev Ther. 2017;11:1815-25. doi: 10.2147/DDDT.S102500.
Alkilani A, McCrudden MT, Donnelly RF. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics. 2015;7(4):438-70. doi: 10.3390/pharmaceutics7040438.
Pola KK, Kumar Rada S. An overview on ultra deformable vesicular drug delivery systems in transdermal drug delivery. Int J App Pharm. 2023 May 7;15(3):28-34. doi: 10.22159/ijap.2023v15i3.46785.
Xu Y, Zhao M, Cao J, Fang T, Zhang J, Zhen Y. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. Acta Pharm Sin B. 2023;13(11):4417-41. doi: 10.1016/j.apsb.2023.05.025. PMID 37969725.
Alkilani AZ, Nasereddin J, Hamed R, Nimrawi S, Hussein G, Abo-Zour H. Beneath the skin: a review of current trends and future prospects of transdermal drug delivery systems. Pharmaceutics. 2022;14(6):1152. doi: 10.3390/pharmaceutics14061152, PMID 35745725.
Lei W, Yu C, Lin H, Zhou X. Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo. Asian Journal of Pharmaceutical Sciences. 2013;8(6):336-45. doi: 10.1016/j.ajps.2013.09.005.
Jire DS, Gosavi NS, Badhe RB, Jagdale DH. Mouth dissolving tablet: a novel drug delivery system. Asian J Pharm Res. 2021;14:180-6. doi: 10.52711/2231-5691.2021.00033.
Rao Y, Zheng F, Zhang X, Gao J, Liang W. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech. 2008;9(3):860-5. doi: 10.1208/s12249-008-9124-y.
Ramadon DE, Pramesti SS, Anwar EF. Formulation, stability test and in vitro penetration study of transethosomes containing green tea (Camellia sinensis L. Kuntze) leaves extract. Int J Appl Pharm. 2017;9(5):91-6.
Mohammed MI, Makky AM, Abdellatif MM. Formulation and characterization of ethosomes bearing vancomycin hydrochloride fo transdermal delivery. Int J Pharm Pharm Sci. 2014;6(11):190-4.
Hanumanaik M, Patil U, Kumar G, Patel SK, Singh I, Jadatkar K. Design, evaluation and recent trends in transdermal drug delivery system: a review. Int J Pharm Sci Res. 2012;3(8):2393.
Nimisha SK, Singh AK. Formulation and evaluation of seabuckthorn leaf extract loaded ethosomal gel. Asian J Pharm Clin Res. 2015;8:309-12.
Shen LN, Zhang YT, Wang Q, Xu L, Feng NP. Enhanced in vitro and in vivo skin deposition of apigenin delivered using ethosomes. International Journal of Pharmaceutics. 2014;460(1-2):280-8. doi: 10.1016/j.ijpharm.2013.11.017.
Javaid A, Singh A, Sharma KK, Abutwaibe KA, Arora K, Verma A. Transdermal delivery of niacin through polysaccharide films ameliorates cutaneous flushing in experimental wistar rats. AAPS PharmSciTech. 2024 May 7;25(5):101. doi: 10.1208/s12249-024-02812-y, PMID 38714629.
Menon S, Verma DE, Khuroo T, Talegaonkar S, Iqbal Z. Extraction of a water-soluble bioactive hypoxoside and its development into an ethosomal system for deep dermal delivery. Int J Pharm Pharm Sci. 2015 Nov 1;7:211-5.
Wagh MP, BORA SS. Development optimization of rizatriptan benzoate ethosomes. Int J App Pharm. 2018;10(2):83-90. doi: 10.22159/ijap.2018v10i2.24354.
Astuti KF, Surini S, Bahtiar AN. Advances in ameliorating rheumatoid arthritis by andrographolide ethosome-based gel: pharmacokinetic and activity study in rats. Int J App Pharm. 2023 Jan 1;15(1):79-86. doi: 10.22159/ijap.2023v15i1.46350.
Saraswathi TS, Roshini R, Damodharan N, Mothilal M, Janani SK. Development of lipid-based vesicles of terbinafine gel for skin delivery by 32 fullfactorial design. Int J Appl Pharm. 2024;16(4):231-43. doi: 10.22159/ijap.2024v16i4.50460J.
Kusuma A, Santosh Kumar R. Optimization of fast-dissolving tablets of carvedilol using 23 factorial design. Int J App Pharm. 2024 Jan;16(1):98-107. doi: 10.22159/ijap.2024v16i1.49535.
Mustofa RR, Iskandarsyah. Preparation and characterization of anti-acne ethosomes using cold and thin-layer hydration methods. Int J App Pharm. 2018;10;1:338-42. doi: 10.22159/ijap.2018.v10s1.75.
Nagadivya N, Vasudha B. Quality by design enables formulation development of zolmitriptan loaded ethosomal intranasal gel for brain targeting: in vitro and ex vivo evaluation. Int J Appl Pharm. 2024;16(4):142-53.
Ashok M, Habibuddin M, Raju J. Provesicular based colloidal carriers for transdermal drug delivery: formulation aspects and bioavailability enhancement of acyclovir proliposomal gels. Int J Pharm Investig. 2021 Apr 1;11(2):195-203. doi: 10.5530/ijpi.2021.2.35.
Jukanti R, Sheela S, Bandari S, Veerareddy PR. Enhanced bioavailability of exemestane via proliposomes based transdermal delivery. J Pharm Sci. 2011;100(8):3208-22. doi: 10.1002/jps.22542, PMID 21404279.
Ashok M, Habibuddin M, Raju J. Provesicular based colloidal carriers for transdermal drug delivery: formulation aspects and bioavailability enhancement of acyclovir proliposomal gels. JPHI. 2021;11(2):195-203. doi: 10.5530/ijpi.2021.2.35.
Published
How to Cite
Issue
Section
Copyright (c) 2024 NALLAGANDLA RAJITHA, KOTHAPALLY DANIEL
This work is licensed under a Creative Commons Attribution 4.0 International License.
